Efficacy and Safety of Selective Digestive Decontamination in the ICU With High Rates of Antibiotic-resistant Bacteria
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Secondary infections remain a major cause of mortality in critically ill patients, mainly
because of high prevalence of multidrug-resistant microorganisms. Therefore strategies aimed
to reduce the incidence of ventilator-associated pneumoniae (VAP) and bloodstream infections
are of utmost important. There is robust data on selective digestive decontamination (SDD)
efficacy in reduction of secondary infections in intensive care units (ICU) with low rates of
antibacterial resistance. However the data received from hospitals with moderate-to-high
rates of resistance is equivocal.
This as an interventional parallel open-label study investigating the effect of selective
digestive decontamination on the rates of ventilator-associated pneumonia in critically ill
patients admitted to the ICU with high prevalence of drug-resistant bacteria. Secondary
outcomes include rates of bloodstream infections, mortality, duration of mechanical
ventilation, duration of ICU stay, resistance selection and overall antibiotic consumption.
Phase:
N/A
Details
Lead Sponsor:
MEDSI Clinical Hospital 1, ICU
Treatments:
Amphotericin B Anti-Bacterial Agents Cefotaxime Cefoxitin Ceftriaxone Gentamicins Liposomal amphotericin B Polymyxin B Polymyxins Vancomycin